

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 31/445, 31/24	A1	(11) International Publication Number: WO 98/52567 (43) International Publication Date: 26 November 1998 (26.11.98)
(21) International Application Number: PCT/US97/08378 (22) International Filing Date: 20 May 1997 (20.05.97) (71)(72) Applicants and Inventors: CALDWELL, Larry, J. [US/US]; 4146 Cranford Circle, San Jose, CA 95124 (US). GALER, Bradley, Stuart [US/US]; 7409 Woodlawn Avenue, N.E., Seattle, WA 98115 (US). (74) Agents: BOZICEVIC, Karl et al.; Bozicevic & Reed LLP, Suite 200, 285 Hamilton Avenue, Palo Alto, CA 94301 (US).	(81) Designated States: AU, CA, JP, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i>	
(54) Title: METHOD FOR TREATING HEADACHE PAIN WITH TOPICAL LOCAL ANESTHETIC COMPOSITIONS (57) Abstract Methods are provided for the treatment of a host suffering from headache pain with topical applications of a local anesthetic. The topical local anesthetic composition comprises an effective amount of a local anesthetic in combination with eucalyptol as a penetration enhancing agent, and optionally an additional penetration enhancing agent. The topical local anesthetic composition is applied to a keratinized skin site proximal to target nerves associated with the headache pain, usually to the supraorbital or occipital regions of the head. Upon application of the topical composition, the local anesthetic rapidly penetrates the skin to block conduction in the target nerves and provide pain relief to the host.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NQ	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

- 1 -

METHOD FOR TREATING HEADACHE PAIN WITH TOPICAL
LOCAL ANESTHETIC COMPOSITIONS

INTRODUCTION

5 Field of the Invention

The field of this invention is the treatment of
headache pain.

Background

Headaches are a common problem affecting a large
10 segment of the population. Headaches, such as tension
type and migraine headaches, occur both intermittently
and chronically, and can arise in response to variety of
stimulants, including stress, injury, toxins in the
environment and the like.

15 A variety of therapeutic agents have been
developed for use in the treatment of patients suffering
from headache pain. Some agents, such as aspirin,
acetaminophen, vasoconstrictors and NSAIDs, e.g.
ibuprofen and naprosyn, are administered systemically.
20 Despite the prevalence of this form of treatment for
headache pain, in some cases, systemic administration is
not recommended. For example, oral administration of
aspirin can result in stomach upset and patient
discomfort. Furthermore, the agent can exert host
25 systemic toxicity which may outweigh any therapeutic
benefits provided by the agent. Finally, since the agent

- 2 -

is administered systemically, its effects are also systemic, which may not be desired.

In view of the above problems and disadvantages associated with therapeutic agents that are administered systemically, regional administration of local anesthetics which selectively block conduction in target nerves is a desirable alternative for the treatment of headache pain. Use of local anesthetics is desirable because nerve conduction can be selectively blocked in only those nerves associated with the headache pain. Although use of local anesthetics in the treatment of headache pain is desirable, administration of an effective amount of the local anesthetic to the target nerves is difficult and/or inconvenient.

For example, a local anesthetic can be injected directly at the site of nerves associated with headache pain, e.g. the occipital and supraorbital nerves to effect a nerve block and thereby provide pain relief. See Garron, "Relieving Pain with Nerve Blocks," Geriatrics (1978) 33: 49-57. Although this method is effective in providing headache pain relief, because the local anesthetic is injected it must be administered by trained personnel. Furthermore, the patient must bear the discomfort associated with the injection of the local anesthetic.

Because of these disadvantages of administration by injection, the topical administration of local anesthetics is a desirable alternative mode of administration. However, local anesthetics by themselves

- 3 -

do not readily penetrate the keratinized layer of the skin. See Review of Medical Pharmacology (Meyers et al. ed., 1978) pp. 217-226. Thus, intranasal application of local anesthetics has found use in the treatment of
5 headache pain. See Brandt et al., "Cluster headache and chronic paroxysmal hemicrania: current therapy," Nervenarzt (1991) 62: 329-339.

For topical administration of local anesthetics to keratinized skin surfaces, additional measures must be
10 taken to provide for penetration of the local anesthetic across the keratinized skin surface. One means of providing for penetration of the local anesthetic across the skin surface is to employ iontophoretic techniques, where an electric field is applied to the topical local
15 anesthetic composition. The local anesthetic penetrates the keratinized skin surface under the influence of the applied electric field.

Another means of providing for penetration of keratinized skin is to employ formulations which promote
20 local anesthetic penetration. Although such formulations are available and have been employed for a variety of applications, currently available topical local anesthetic formulations have not found widespread use for the treatment of headache pain. One reason that currently
25 available formulations have not found widespread use for the treatment of headache pain is that an effective amount of the anesthetic agent does not penetrate the skin rapidly enough to provide pain relief in a sufficiently short period of time. For example, when EMLA

- 4 -

(a eutectic mixture of lidocaine and prilocaine) is topically applied to a keratinized skin surface, it must be applied under an occlusive dressing for at least one hour before analgesia is experienced by the host. See
5 Physician's Desk Reference, 1994, pp 544.

Thus, there is continued interest in the identification of topical local anesthetic formulations which are suitable for use in the treatment of headache pain. Such topical formulations should provide for rapid
10 penetration of an effective amount of the local anesthetic through the skin surface, and thereby provide for rapid pain relief.

Relevant Literature

U.S. Patent No. 4,440,777 describes topical
15 applications comprising eucalyptol as an enhancing agent. Other patents of interest include U.S. Pat. Nos.: 4,588,580; 4,911,707; 5,069,909; 5,070,084; 5,330,452; and 5,368,860.

Kittrelle et al., "Cluster Headache. Local
20 Anesthetic Abortive Agents," Arch. Neurol. (1985) 42: 496-498 reports the application of a 4% lidocaine solution to the sphenopalantine fossa in order to treat nitrate induced cluster headache pain.

SUMMARY OF THE INVENTION

25 Methods are provided for the treatment of a host suffering from headache pain with topical local anesthetic compositions. Topical local anesthetic

- 5 -

compositions employed in the subject methods comprise an effective amount of a local anesthetic in combination with eucalyptol as a penetration enhancing agent. The local anesthetic compositions are applied to a

5 keratinized skin site proximal to target nerves associated with the headache pain. Upon application, the local anesthetic rapidly penetrates the skin surface to reach, and block conduction in, the target nerves and provide for rapid pain relief.

10 DESCRIPTION OF THE SPECIFIC EMBODIMENTS

Methods are provided for the treatment of a host suffering from headache pain through application of topical local anesthetic compositions. The local anesthetic compositions employed in the subject methods

15 comprise an effective amount of a local anesthetic in combination with eucalyptol as a penetration enhancing agent and provide for rapid penetration of the local anesthetic agent through a keratinized skin surface. In the subject methods, the local anesthetic composition is

20 topically applied to a skin site proximal to target nerves associated with the headache pain. Upon application, the local anesthetic agent penetrates the skin to block conduction in the target nerves and provide pain relief to the host.

25 Topical compositions employed in the subject method will include a local anesthetic as the active agent. Although two or more local anesthetic agents may be present in the subject compositions, generally the

- 6 -

subject compositions will comprise a single local anesthetic agent. The local anesthetic employed in the subject methods will be an anesthetic which, when administered in the topical formulations, rapidly
5 penetrates a keratinized skin surface to block conduction in nerves underlying the skin surface. The local anesthetic will have a molecular weight and melting point that is compatible with transport across the keratinized skin surface. Generally, the molecular weight of the
10 local anesthetic will not exceed about 300 dal, and will more usually not exceed about 250 dal. The melting point of the local anesthetic will be less than about 100 °C. Generally, the local anesthetic will be a compound comprised of a secondary or tertiary amine linked through
15 a connecting group to an aromatic group. The local anesthetic will be an alkanyl compound of from about 9 to 20 carbon atoms. Because the composition is applied topically, the local anesthetic will generally be present in the composition as a free base to promote penetration
20 of the agent through the skin surface. A large number of local anesthetics are known in the art, many of which are suitable for topical application. Suitable local anesthetics include lidocaine, butamben, butanilicaine, ethyl aminobenzoate, fomocaine, hydroxyprocaine, isobutyl
25 p-aminobenzoate, naepaine, octacaine, parethoxycaine, piridocaine, prilocaine, procaine, risocaine, tolycaine, trimecaine, particularly ethylaminobenzoate (benzocaine). The amount of local anesthetic present in the subject compositions will be sufficient to provide an effective

- 7 -

amount of the agent when topically administered according to the subject methods. The precise amount of anesthetic agent present in the topical formulation will depend on the particular agent employed, but will generally range
5 from 5 to 50 % by weight, usually from about 10 to 40 % by weight.

Critical to the topical applications employed in the subject methods is eucalyptol, which serves as a penetration enhancing agent for the local anesthetic.
10 Eucalyptol (1,3,3-trimethyl-2-oxabicyclo[2,2,2]-octane) is the chief constituent of oil of eucalyptus and is also known as cineole and cajeputol. Eucalyptol is known in the art, having found use as an insect repellant and as a flavoring agent. The amount of eucalyptol present in the
15 composition will range from about 10 to 80%, usually from about 10 to 50 % by weight, and more usually from about 20 to 40 % by weight of the composition.

Optionally, the subject composition may further comprise one or more additional penetration enhancing
20 agents which work in combination with the eucalyptol to provide for rapid penetration of the local anesthetic. Additional penetration enhancing agents will be capable of rapid penetration of the skin and be pharmaceutically acceptable, i.e. non-toxic to the host at the levels at
25 which they are present in the composition. Examples of additional penetration enhancing agents which may find use in the subject compositions include: propylene glycol and N-methyl-2-pyrrolidone. An additional penetration enhancing agent that finds particular use in combination

- 8 -

with eucalyptol in the subject compositions is N,N-diethyl-m-toluamide (DEET). When present, the amount of this additional penetration enhancing agent in the subject compositions will vary depending on the particular agent, as well as the local anesthetic present in the composition. The amount of additional penetration enhancing agent or agents in the subject compositions will range from 10 to 80 % by weight, usually from about 30 to 60 % by weight. Generally, the ratio of eucalyptol to additional penetration enhancing agent in the subject compositions will be from 0.25:1 to 2:1, and will usually be from about 1:2 to 1:1.

The compositions comprising the local anesthetic, eucalyptol and any additional penetration enhancing agent employed in the subject methods will be formulated in a manner convenient for topical application. Thus, the subject compositions may be formulated as stable solutions or suspensions of the local anesthetic in eucalyptol. Alternatively, the local anesthetic and eucalyptol may be combined with one or more carrier materials to form a solution, suspension, gel, lotion, cream, ointment, aerosol spray or the like, as is known in the art.

Gel vehicles in which the subject local anesthetic and eucalyptol may be formulated to produce a topical application useful in the subject methods will be physiologically acceptable and will generally comprise a solvent in combination with a thickening agent. The solvent will generally be an alkanol, such as an alcohol.

- 9 -

or polyol, including: ethanol, isopropanol, propylene glycol, glycerol, and the like. These alcohols and polyols may be used individually or in combination. In the gel vehicle, the solvent will generally be present in 5 from about 1 to 80 weight %, more commonly 10 to 40 weight % of the topical composition.

Conventional gelling or thickening agents may be employed to provide for a formulation which can be conveniently applied to the skin. Gelling agents which 10 have been found to be effective and are illustrative of conventionally used gelling agents for skin application include Carbomer 940 (neutralized with diisopropanolamine), neutralized polyacrylic acid, etc. The gelling agent will be used in an amount sufficient to 15 provide the appropriate viscosity, generally being in the range of about 0.1-5 weight percent of the formulation.

Non-ionic surfactants may be included in the compositions, where the nonionic surfactants may serve as cosolvents and epidermal penetration enhancers, in 20 addition to the eucalyptol and any optional penetration enhancing agent described above. Conventional surfactants may be employed, which are physiologically acceptable, such as sorbitan esters, etc. When present, the nonionic surfactant will generally be present in an 25 amount of from about 2-20 weight percent of the formulation.

The topical composition may also contain other physiologically acceptable excipients or other minor additives, particularly associated with organoleptic

- 10 -

properties, such as fragrances, dyes, emulsifiers, buffers, cooling agents (e.g. menthol), antibiotics, stabilizers or the like. The excipients and minor additives will be present in conventional amounts ranging
5 from about 0.001% to 5%, more commonly 0.001-2%, by weight, usually not exceeding a total of 10% by weight.

Where convenient, e.g. with a gel formulation, the topical application may be covered with an occlusive dressing, which may be porous or non-porous, so as to
10 protect the gel from mechanical removal during the period of treatment. Various inert coverings may be employed, which include the various materials which may find use in plasters, described below. Alternatively, non-woven or woven coverings may be employed, particularly elastomeric
15 coverings, which allow for heat and vapor transport. These coverings allow for cooling of the pain site, which provides for greater comfort, while protecting the gel from mechanical removal.

Instead of a gel, a plaster may be employed, where
20 the composition comprising the local anesthetic and eucalyptol, and any additional penetration enhancers, may be formulated into the adhesive of the plaster. In the case of plasters, the coverings may include polyvinyl chloride, polyvinylidene chloride, (SARAN®),
25 polyethylene, synthetic rubber, woven or nonwoven polyester fabric, etc. The local anesthetic and the eucalyptol may be combined with the adhesive with the aid of a cosolvent, or a combination of cosolvents, such as propylene glycol, glycerin, methyl salicylate, glycol

- 11 -

salicylate, or the like. The particular choice of adhesive is not critical, there being a wide variety of physiologically acceptable adhesives, which can maintain the local anesthetic, eucalyptol and any additional
5 penetration enhancing agent, in contact with the skin.

Of particular interest are the topical local anesthetic compositions described in U.S. Pat. No. 4,440,777, the disclosure of which is herein incorporated by reference.

10 In the subject methods, the topical composition comprising the local anesthetic is applied to a keratinized skin site of the host proximal to target nerves associated with the headache pain. Nerves which are commonly associated with headache pain are the
15 occipital and supraorbital nerves. The skin site at which the composition is applied will be sufficiently proximal to the target nerves, e.g. the skin site overlies the region innervated by the target nerves, so that upon contact of the composition with the skin surface, the
20 local anesthetic can readily reach the target nerves and exert its anti-conduction activity. Of particular interest as skin sites of topical application are the supraorbital and occipital regions.

The subject compositions will be applied to the
25 skin site for a period of time ranging from .25 to 6 hours, usually from about .5 to 5 hours, during which time the host will experience relief from pain due to the activity of the local anesthetic on the target nerves. If headache pain recurs following removal of the topical

- 12 -

composition, a new topical composition may be applied. The process may be repeated as necessary and desired to achieve pain relief. Because of the nature of the topical local anesthetic composition employed in the subject
5 methods, penetration of the local anesthetic is rapid. Therefore, the patient experiences relief from the pain shortly after application. Usually the patient will experience at least some relief from the headache pain about .25 to 30 min following application of the topical
10 composition, usually about .5 to 30 min following application of the topical composition.

The amount of composition applied will usually be sufficient to cover a majority of the region of skin overlying the target nerves to ensure that conduction in
15 a sufficient percentage of the target nerves is blocked, so that the host experiences pain relief. The exact amount of topical composition that is applied may be determined empirically. For example, where the topical application is applied to the supraorbital region of the
20 head, the amount of composition applied will be sufficient to cover at least about 50 %, more usually at least about 75 % of the region. For solutions, dispersions, gels, lotions, creams and the like, the composition will be spread over the region and a covering
25 optionally applied thereto. For patches, an appropriate sized patch will be placed over the region comprising the skin site.

Conveniently, the composition may be provided in a unit dosage format, which formats are known in the art.

- 13 -

Upon application of the topical composition, the local anesthetic rapidly penetrates the surface of the skin and blocks conduction of the target nerves which are proximal to the skin site. As a result, the patient will
5 experience at least a partial subsidence in the intensity of headache pain, and in some cases may experience a complete cessation of pain. Thus, application of the topical local anesthetic compositions in accordance with the subject methods results in treatment of the host
10 suffering from headache pain.

The following examples are offered by way of illustration and not by way of limitation.

EXPERIMENTAL

15 A mixture of DEET (N,N-diethyl-m-toluamide) and eucalyptol (1,3,3-trimethyl-2-oxabicyclo [2,2,2]-octane) was prepared in a ratio of 2:1. A sufficient amount of benzocaine free base (ca. 30% by weight) was dissolved in the mixture to produce a saturated solution of the local
20 anesthetic.

The solution was topically applied to a female patient suffering from acute migraine without aura. The solution was applied directly to the areas of the patient's head where the supraorbital and occipital
25 nerves are closest to the skin (the same area in which a needle would be inserted to perform regional anesthesia to these nerves). Prior to application of the solution,

- 14 -

the patient rated her headache pain as "moderate" with "moderate" nausea and "moderate" light sensitivity.

After 15 minutes, the headache pain had subsided to a level described by the patient as "very mild."

5 Furthermore, the patient reported no nausea or light sensitivity. In addition, the patient did not develop any noise sensitivity, which in the past had typically become sever during previous migraine attacks.

The patient's relief from the pain and other
10 migraine symptoms lasted in excess of 2 hours. The patient was able to continue working following application of the topical local anesthetic solution. This was a favorable result compared to other forms of treatment which the patient had employed previously,
15 where, despite treatment, the patient had to stop working.

It is evident from the above results and discussion that a novel and effective method of treating headache pain in a host is provided. The nature of the
20 topical applications employed provides for rapid penetration of the skin surface by the local anesthetic. As a result, the patient experiences pain relief shortly after application of the composition. Furthermore, since the local anesthetic composition is topical, the method
25 is convenient and tolerated well by patients.

All publications and patent applications cited in this specification are herein incorporated by reference .

- 15 -

as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference.

Although the foregoing invention has been
5 described in some detail by way of illustration and example for purposes of clarity of understanding, it will be readily apparent to those of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications may be made thereto without
10 departing from the spirit or scope of the appended claims.

- 16 -

WHAT IS CLAIMED IS:

1. A method for treating a host suffering from headache pain by blocking conduction in target nerves associated with said headache pain, said method comprising:
5 applying at a keratinized skin site proximal to said target nerves a topical local anesthetic composition comprising: an effective amount of a local anesthetic in combination with eucalyptol as a penetration enhancing
10 agent;
whereby said local anesthetic rapidly penetrates the skin surface at said skin site to block conduction in said target nerves.
2. The method according to Claim 1, wherein said
15 topical local anesthetic composition further comprises an additional penetration enhancing agent.
3. The method according to Claim 1, wherein said target nerves are selected from the group consisting of the occipital and supraorbital nerves..
- 20 4. A method for treating a host suffering from headache pain by blocking conduction in target nerves associated with said headache pain, said method comprising:
applying at a keratinized skin site proximal to
25 said target nerves a topical local anesthetic composition

- 17 -

comprising: (a) an effective amount of a local
anesthetic, where in said local anesthetic is an amine
linked through a connecting group to an aromatic group;
(b) eucalyptol as a penetration enhancing agent and (c)
5 an additional penetration enhancing agent, wherein said
target nerves are selected from the group consisting of
occipital and supraorbital nerves;

whereby said local anesthetic rapidly penetrates
the skin at said skin site to block conduction in said
10 target nerves.

5. The method according to Claim 4, wherein said
local anesthetic is bupivacaine.

6. The method according to Claim 4, wherein said
additional penetration enhancing agent is N,N-diethyl-m-
15 toluamide.

7. A method for treating a host suffering from
headache pain by blocking conduction in target nerves
selected from the group consisting of the occipital and
supraorbital nerves, said method comprising:

20 applying at a keratinized skin site proximal to
said target nerves a topical local anesthetic composition
comprising: (a) an effective amount of benzocaine, (b)
eucalyptol and (c) N,N-diethyl-m-toluamide;

whereby said bupivacaine rapidly penetrates the
25 skin at said skin site to block conduction in said target
nerves.

- 18 -

8. The method according to Claim 7, wherein said benzocaine is present in said composition in amount ranging from 20 to 40 % by weight.
9. The method according to Claim 7, wherein the ratio of said eucalyptol to N,N-diethyl-m-toluamide in said composition is 1:2.
10. The method according to Claim 7, wherein said composition is formulated as a gel.
11. The method according to Claim 7, wherein said gel is covered with a dressing.
12. The method according to Claim 7, wherein said composition is formulated into the adhesive of a plaster.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US97/08378

A. CLASSIFICATION OF SUBJECT MATTER IPC(6) :A61K 31/445, 31/24 US CL :514/330, 535, 536 According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) U.S. : 514/330, 535, 536 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) Please See Extra Sheet.		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 4,440,777 A (ZUPAN) 03 APRIL 1984, see particularly claims 1-11.	1-12
Y	US 4,466,973 A (RENNIE) 21 AUGUST 1984, entire document.	1-12
Y	Database CA on STN, American Chemical Society (Columbus, Ohio) No. 126:162284 CA, LIEDTKE. R. K. Local Anesthetics for Topical Treatment of Headache. Abstract, EP 754453, 22 Jan 1997, see entire document.	1-12
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *A* document defining the general state of the art which is not considered to be of particular relevance *E* earlier document published on or after the international filing date *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or other means *P* document published prior to the international filing date but later than the priority date claimed *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art *Z* document member of the same patent family	
Date of the actual completion of the international search 16 JULY 1997		Date of mailing of the international search report 24 SEP 1997
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231		Authorized officer WILLIAM HARVIS
Facsimile No. (703) 305-3230		Telephone No. (703) 308-1235

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US97/08378

B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

APS, STN (CA, BIOSIS, MEDLINE)

search terms: eucalyptol, anaesthetic, anesthetic, bupivacaine, benzocaine, toluidamide, transdermal, transcutaneous, topical, headache, pain